Brief: Inflarx Initiates First-In-Human Study With Small Molecule C5ar Inhibitor Inf904
09/11/2022 15:54
Nov 9 (Reuters) - InflaRx NV IF0G.F :
* INFLARX INITIATES FIRST-IN-HUMAN STUDY WITH SMALL MOLECULE
C5AR INHIBITOR INF904
Source text for Eikon: ID:nGNX4Wd48B
Further company coverage: IF0G.F
((reuters.briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum